ZA201306402B - Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) - Google Patents

Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Info

Publication number
ZA201306402B
ZA201306402B ZA2013/06402A ZA201306402A ZA201306402B ZA 201306402 B ZA201306402 B ZA 201306402B ZA 2013/06402 A ZA2013/06402 A ZA 2013/06402A ZA 201306402 A ZA201306402 A ZA 201306402A ZA 201306402 B ZA201306402 B ZA 201306402B
Authority
ZA
South Africa
Prior art keywords
azacycles
condensed
processes
preparation
crystalline forms
Prior art date
Application number
ZA2013/06402A
Other languages
English (en)
Inventor
Anthony C Blackburn
Robert M Jones
Biman B Pal
Sangdon Han
Jaimie Karyn Rueter
Anthonio Garrido Montalban
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of ZA201306402B publication Critical patent/ZA201306402B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2013/06402A 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) ZA201306402B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (1)

Publication Number Publication Date
ZA201306402B true ZA201306402B (en) 2022-03-30

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06402A ZA201306402B (en) 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP4166552B1 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596913B (zh) 2009-08-28 2016-11-09 艾尼纳制药公司 大麻素受体调节剂
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
EA201892280A1 (ru) * 2016-04-10 2019-04-30 Арена Фармасьютикалз, Инк. Способы лечения селективными агонистами cb-рецептора
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
MX2019013311A (es) * 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2023059610A1 (en) 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费-阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
WO2003049727A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体,含有该配体的药物组合物及其制备方法
PL1902034T3 (pl) * 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
SI2081572T1 (sl) 2006-07-04 2010-06-30 Janssen Pharmaceutica Nv Benzimidazolni kanabinoidni agonisti ki nosijo substituirano heterociklično skupino
EA200900403A1 (ru) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
US20080200501A1 (en) 2006-11-03 2008-08-21 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US20090325936A1 (en) 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
EP2142531B1 (en) 2007-03-30 2015-07-08 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102596913B (zh) * 2009-08-28 2016-11-09 艾尼纳制药公司 大麻素受体调节剂
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора

Also Published As

Publication number Publication date
US20140135345A1 (en) 2014-05-15
KR102036932B1 (ko) 2019-10-25
AU2012222146B2 (en) 2017-05-11
CA2827057A1 (en) 2012-08-30
US20190308952A1 (en) 2019-10-10
EP4166552B1 (en) 2025-03-19
US11560369B2 (en) 2023-01-24
AU2012222146A1 (en) 2013-09-19
EP3395812B8 (en) 2022-11-02
MY165767A (en) 2018-04-23
BR112013021549B1 (pt) 2022-01-11
EP2678330A1 (en) 2014-01-01
CN103608343A (zh) 2014-02-26
EP3395812A1 (en) 2018-10-31
US20210380560A1 (en) 2021-12-09
SG192817A1 (en) 2013-09-30
ES2932441T3 (es) 2023-01-19
BR112013021549A2 (pt) 2016-11-01
DK3395812T3 (da) 2022-11-28
US10981895B2 (en) 2021-04-20
PH12013501726A1 (en) 2014-01-13
CL2013002436A1 (es) 2014-01-24
EA201391233A1 (ru) 2014-02-28
JP2014506602A (ja) 2014-03-17
EA035989B1 (ru) 2020-09-09
CN103608343B (zh) 2019-02-01
CO6852066A2 (es) 2014-01-30
MX2013009760A (es) 2014-06-11
US10183930B2 (en) 2019-01-22
IL227782A (en) 2017-02-28
MX346533B (es) 2017-03-14
EP3395812B1 (en) 2022-09-28
IL227782A0 (en) 2013-09-30
US9458136B2 (en) 2016-10-04
JP5945554B2 (ja) 2016-07-05
CA2827057C (en) 2022-06-07
WO2012116276A1 (en) 2012-08-30
NZ614787A (en) 2014-08-29
KR20140025353A (ko) 2014-03-04
US20170144993A1 (en) 2017-05-25
EP4166552A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
ZA201306402B (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
ZA201305972B (en) Method for the preparation of biphephos
SG10201501575VA (en) Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
HUE037511T2 (hu) Eljárás toluol-diamin elõállítására dinitro-toluol hidrogénezésével
PL3656758T3 (pl) Półprodukty do przygotowania c-końcowych inhibitorów hsp90
SG11201400939YA (en) Process for the preparation of methoxymelonal
ZA201403736B (en) Process for the preparation of sterol derivatives
ZA201303467B (en) Method for the preparation of high-purity pharmaceutical intermediates
PL2552925T3 (pl) Sposób wytwarzania azodikarbamidów zawierających krzem
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
DK2429996T3 (en) Process for the preparation of histamine h3 receptor modulators
HUE036284T2 (hu) Eljárás szilícium-karbid elõállítására
PL2702045T3 (pl) Nowy sposób sporządzania Etrawiryny
PT2390246T (pt) Processo para a preparação de aminaftona
HK1193088A (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
ZA201303653B (en) Process for the preparation of gaseous synfuel
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
PL391682A1 (pl) Sposób otrzymywania ε-kaprolaktonu
ZA201208583B (en) Process for the preparation of hydroquinones
IL224304A (en) A process for making dichlorobulben
AU2011904710A0 (en) Device for Enhancing the Boarding of Aircraft
PL394782A1 (pl) Sposób otrzymywania zwiazków epoksydowych na katalizatorze tytanowo-silikalitowym